JPMORGAN CHASE & CO - SPARK THERAPEUTICS INC ownership

SPARK THERAPEUTICS INC's ticker is ONCE and the CUSIP is 84652J103. A total of 180 filers reported holding SPARK THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 2.24 and the average weighting 0.2%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of SPARK THERAPEUTICS INC
ValueSharesWeighting
Q3 2019$48,484,000
-30.5%
499,936
-26.8%
0.01%
-28.6%
Q2 2019$69,790,000
-40.5%
683,015
-33.7%
0.01%
-41.7%
Q1 2019$117,392,000
+20.8%
1,030,842
-58.5%
0.02%
+9.1%
Q4 2018$97,203,000
-23.5%
2,483,445
+6.7%
0.02%
-8.3%
Q3 2018$126,988,000
-33.4%
2,327,904
+1.1%
0.02%
-38.5%
Q2 2018$190,561,000
+18.5%
2,302,567
-4.7%
0.04%
+14.7%
Q1 2018$160,829,000
+39.7%
2,415,207
+7.8%
0.03%
+41.7%
Q4 2017$115,159,000
-30.2%
2,239,585
+21.1%
0.02%
-33.3%
Q3 2017$164,986,000
+71.8%
1,848,988
+15.0%
0.04%
+63.6%
Q2 2017$96,060,000
+16.3%
1,607,972
+3.8%
0.02%
+15.8%
Q1 2017$82,628,000
+15.3%
1,549,093
+7.8%
0.02%
+11.8%
Q4 2016$71,681,000
-10.7%
1,436,497
+7.5%
0.02%
-15.0%
Q3 2016$80,269,000
+16.3%
1,336,491
-1.0%
0.02%
+17.6%
Q2 2016$69,003,000
+244.2%
1,349,580
+98.7%
0.02%
+240.0%
Q1 2016$20,045,000
-25.3%
679,220
+14.6%
0.01%
-28.6%
Q4 2015$26,848,000
+1168.2%
592,561
+1068.4%
0.01%
+600.0%
Q3 2015$2,117,000
-60.9%
50,716
-43.6%
0.00%0.0%
Q2 2015$5,417,000
+62.5%
89,886
+109.0%
0.00%0.0%
Q1 2015$3,333,00042,9980.00%
Other shareholders
SPARK THERAPEUTICS INC shareholders Q2 2018
NameSharesValueWeighting ↓
Casdin Capital, LLC 93,500$5,616,0004.55%
Rock Springs Capital Management LP 625,000$37,538,0002.35%
Bain Capital Public Equity Management, LLC 367,314$22,061,0001.43%
EcoR1 Capital, LLC 68,600$4,120,0001.26%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 368,000$22,102,0001.03%
Baker Brothers Advisors 1,318,341$79,180,0000.72%
Eventide Asset Management 150,000$9,009,0000.55%
FEDERATED HERMES, INC. 1,633,900$98,132,0000.28%
Iguana Healthcare Management, LLC 25,000$1,502,0000.27%
BAILARD, INC. 40,600$2,442,0000.22%
View complete list of SPARK THERAPEUTICS INC shareholders